LEADER 05607nam 2200769Ia 450 001 9910146240503321 005 20220425093722.0 010 $a1-280-72268-1 010 $a9786610722686 010 $a3-527-60609-2 010 $a1-280-55857-1 010 $a9786610558575 010 $a3-527-60144-9 035 $a(CKB)1000000000019341 035 $a(EBL)482099 035 $a(OCoLC)648321750 035 $a(SSID)ssj0000212536 035 $a(PQKBManifestationID)11198870 035 $a(PQKBTitleCode)TC0000212536 035 $a(PQKBWorkID)10137436 035 $a(PQKB)11302788 035 $a(MiAaPQ)EBC482099 035 $a(MiAaPQ)EBC4957150 035 $a(Au-PeEL)EBL4957150 035 $a(CaONFJC)MIL55857 035 $a(OCoLC)1027172514 035 $a(EXLCZ)991000000000019341 100 $a20030725d2004 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel vaccination strategies$b[electronic resource] /$fedited by Stefan H.E. Kaufmann 210 $aWeinheim $cWiley-VCH$dc2004 215 $a1 online resource (672 p.) 300 $aDescription based upon print version of record. 311 $a3-527-30523-8 320 $aIncludes bibliographical references and index. 327 $aNovel Vaccination Strategies; Contents; Novel Vaccination Strategies; Preface; Acknowledgements; List of Contributors; Colour Plates; Part I; 1 Challenges for the Vaccine Developer, including Correlates of Protection; 1.1 Introduction; 1.2 Mechanisms of Protection within the Immune System; 1.3 Protection against Viruses; 1.4 HIV/AIDS as an Example of a Persisting Virus; 1.5 Protection against Extracellular Bacteria; 1.6 Protection against Intracellular Bacteria; 1.7 Protection against Parasites; 1.8 Conclusions; References; Part II Vaccination and Immune Response 327 $a2 Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses2.1 Introduction; 2.2 Activation of Innate Immunity: Sensing the Enemy; 2.2.1 Pathogen-associated Molecular Patterns; 2.2.2 Host Cellular Sensors; 2.2.2.1 Dendritic Cells; 2.2.2.2 Mast Cells; 2.2.3 Nonpeptide MHC Ligands Triggering Invariant T-cell Receptors; 2.3 Translating Innate Immune Activation into Regulatory Circuits: Molecular Pathways Shaping Adaptive Immunity; 2.3.1 TLR-initiated Signaling Cascades; 2.3.2 Molecules Involved in Recruiting Effector Cells; 2.3.2.1 Defensins; 2.3.2.2 Chemokines 327 $a2.3.3 Molecules Involved in T and B Cell Differentiation2.3.3.1 Th1-inducing Cytokines; 2.3.3.2 Th2-inducing Cytokines; 2.4 Implications for Vaccine Development; References; 3 Adjuvant-induced Th2- and Th1-dominated Immune Responses in Vaccination; 3.1 Introduction; 3.2 The Two-Signal Model of Adjuvant-induced Immune Activation; 3.3 Th1 and Th2 Induction by Vaccine Adjuvants; 3.4 Antigen Dose Effects; 3.5 The Three-signal Model of Adjuvant-induced Immune Activation; 3.6 Th2 Induction by Adjuvants; 3.7 Differential Activation of DCs; 3.8 Inappropriate Th1/Th2 Responses to Vaccines 327 $a3.9 Human Th2 vaccines3.10 Human Th1 Vaccines; 3.11 Conclusion; References; 4 Memory; 4.1 Introduction; 4.2 Characteristics of Memory Cells; 4.3 CD8+ T Cell Memory; 4.3.1 Phenotyping Memory CD8+ T Cells; 4.3.2 Enhanced Responsiveness of Memory CD8(+) T cells: Potential Mechanisms; 4.3.3 Generation of Memory CD8+ T Cells; 4.3.4 Maintaining CD8+ T Cell Memory; 4.3.5 Models of CD8+ T cell Memory Generation; 4.4 CD4+ T Cell Memory; 4.4.1 Differentiation of Effector and Memory CD4+ T Cells; 4.4.2 Phenotype of Memory CD4+ T Cells; 4.4.3 Memory Generation and Maintenance 327 $a4.4.4 Trafficking of Memory CD4+ T Cells4.5 B cell Memory; 4.5.1 Generation of B Cell Memory; 4.5.2 Maintenance of B Cell Memory; 4.6 Conclusions; Acknowledgements; References; 5 T Cell-based Vaccines; Summary; 5.1 Introduction; 5.2 Ex-vivo Detection of Antigen-specific T Cells; 5.3 In-vivo Kinetics of Antigen-specific T Cell Responses; 5.4 Effector Function and Subtypes of Effector T Cells; 5.5 T Cell Receptor Repertoire, Avidity Maturation, and Epitope Competition; 5.6 Functional Heterogeneity of T Cell Memory; 5.7 Vaccination Strategies and Their Efficacy for T Cell-based Vaccination 327 $a5.8 Concluding Remarks 330 $aThe protection mode of most available vaccines is based on antibody responses. Since efficient immune responses to many pathogens rely on activating all arms of the immune system, traditional vaccine development does not provide efficient protection against many diseases. Novel vaccination strategies need to allow presentation of antigens that activate the full array of the immune response in the right composition and should prevent pathogen entry by mobilizing the mucosal immune response. New technological advances optimize the immunogenicity of 'live' and sub-unit vaccines.This book offe 606 $aVaccines 606 $aVaccines$xSynthesis 606 $aVacunes$2thub 606 $aVacunació$2thub 606 $aResposta immunitària$2thub 608 $aElectronic books. 608 $aLlibres electrònics$2thub 615 0$aVaccines. 615 0$aVaccines$xSynthesis. 615 7$aVacunes 615 7$aVacunació 615 7$aResposta immunitària 676 $a615.372 701 $aKaufmann$b S. H. E$g(Stefan H. E.)$0967987 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910146240503321 996 $aNovel vaccination strategies$92870791 997 $aUNINA